Immunogenic Targets for Therapeutic Vaccination for Liver Cancer

Immunogenic Targets for Therapeutic Vaccination for Liver Cancer - ITVALICA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42346

Enrollment

360

Registered

2015-10-20

Start date

2015-09-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer primary liver cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult HCC-patients treated with RFA, TACE, or surgical resection in Erasmus MC, who are planned to be followed up in Erasmus MC for at least 3 months after the intervention.

Exclusion criteria

Exclusion criteria: Patients who refuse to participate in the study (refusing blood/tissue donation). Patients with a severe immunocompromised medical condition, or patients taking immunosuppressing medication.

Design outcomes

Primary

Measure	Time frame
Determination of tumour antigens and viral antigens that are target of naturally occurring T cell and antibody responses upon tumour destruction or debulking by currently applied therapeutic interventions.	—

Secondary

Measure	Time frame
None	—

Countries

Netherlands

Outcome results